Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563, A Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, on Asthma Control Following Acute Exacerbations in Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors MedImmune
- 11 Mar 2019 Results assessing pharmacokinetic (PK) data from nine clinical trials (NCT00512486, NCT00659659, NCT00768079, NCT00783289, NCT01238861, NCT01928771, NCT01914757, NCT02322775, NCT02075255) for patients with asthma, published in the Clinical Pharmacokinetics.
- 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.
- 03 Oct 2011 Actual initiation date changed from Nov 2008 to Feb 2009 as reported by ClinicalTrials.gov.